胸腺肽α_1对慢性肺心病患者细胞免疫及反复呼吸道感染的影响

Influence of thymosin α_1 on cellular immunity and repeated respiratory tract infection in patients with chronic pulmonary heart disease

目的观察胸腺肽α1对慢性肺源性心脏病(肺心病)患者细胞免疫及反复呼吸道感染的影响。方法随机将慢性肺心病患者分为治疗组(胸腺肽α1组)28例,对照组(常规治疗组)22例,采用流式细胞仪检测两组3个月前后外周血CD4+、CD8+以及CD4+/CD8+比值的变化;观察12个月内呼吸道感染的发生率。结果治疗组应用胸腺肽α13个月后,外周血CD4+以及CD4+/CD8+比值均显著升高,12个月内呼吸道感染发生率较对照组显著降低(P<0.05);对照组3个月后CD4+、CD8+以及CD4+/CD8+比值无明显变化,且12个月内呼吸道感染发生率较治疗组明显增多。结论胸腺肽α1能够改善慢性肺心病患者细胞免疫功能,并减少患者反复呼吸道感染的发生率。

Objective To observe the influnce on cellular immunity and repeated respiratory tract infection by thymosin α1 in patients with chronic pulmonary heart disease. Methods The patients with chronic pulmonary heart disease were randomly divided into two groups： treatment group （thymosin α1 group）28 cases, control group （ normal group） 22 cases, the percentage of CD4^＋ , CD8^＋ and CD4^＋/CD8^＋ were tested by flow cytometry technique after 3 months,to observe the incidence rate of respiratory tract infection in 12 months. Results The percentage of CD4^＋ ,CD8^＋ , CD4^＋/CD8^＋ were significantly higher in thymosin α1 group which were treated with thymosin α1 after 3 months, and the incidence rate of respiratory tract infection were significantly higher in control group. Conclusion Thymosin α1 can improve the function of cellular immunity in patients with chronic pulmonary heart disease and decrease the incidence rate of repeated respiratory tract infection.